Synta Announces Presentations at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting
GALAXY-2 trial design
“GALAXY-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma”
Abstract #: TPS8118^
Date and time:
Location:
General Poster Session – Lung Cancer – Non-small Cell Metastatic. S Hall
A2
Presenter:
Trial design for investigator-sponsored trial of ganetespib in sarcoma
“SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST)”
Abstract #: TPS10603
Date and time:
Location:
General Poster Session – Sarcoma. S Hall A2
Presenter:
Ganetespib in pediatric sarcomas (preclinical)
“Heat-shock protein 90 inhibition in pediatric sarcomas”
Abstract #: 10057
Date and time:
Location:
General Poster Session – Pediatric Oncology. S Hall A2
Presenter:
Fernanda Irene Arnaldez, MD, Pediatric Oncology Branch,
About Ganetespib
Ganetespib, an investigational drug candidate, is a selective inhibitor
of heat shock protein 90 (Hsp90), a molecular chaperone which controls
the folding and activation of a number of client proteins that drive
tumor development and progression. Many solid and hematologic tumors are
dependent on Hsp90 client proteins including proteins involved in
“oncogene addiction” (ALK, HER2, mutant BRAF and EGFR, androgen
receptor, estrogen receptor, and JAK2); proteins involved in resistance
to chemotherapy and radiation therapy (ATR, BCL2, BRCA1/2, CDK1/4, CHK1,
survivin, and WEE1); proteins involved in angiogenesis (HIF-1alpha,
VEGFR, PDFGR, and VEGF); and proteins involved in metastasis (MET, RAF,
AKT, MMPs, HIF-1alpha, and IGF-1R). In preclinical models, inhibition of
Hsp90 by ganetespib results in the inactivation, destabilization, and
eventual degradation of these cancer-promoting proteins. Ganetespib is
being evaluated in trials in lung cancer, breast cancer, and other tumor
types. The most common adverse event seen to date has been transient,
mild or moderate diarrhea, which has been manageable with standard
supportive care. Information on these trials can be found at www.clinicaltrials.gov.
Ganetespib has received Fast Track designation from
About
Source:
Synta Pharmaceuticals Corp.
Steven Bernitz, 781-541-7250
Senior
Vice President, Corporate Development
[email protected]
or
Argot
Partners
Andrea Rabney, 212-600-1494
[email protected]
or
Argot
Partners
Eliza Schleifstein, 917-763-8106
[email protected]